HYPR vs GEHC

For growth investors, Hyperfine, Inc.

(HYPR) is the stronger pick with 5. 2% revenue growth year-over-year, versus 4. 8% for GE HealthCare Technologies Inc. (GEHC). GE HealthCare Technologies Inc. (GEHC) offers the better valuation at 13. 5x trailing P/E (12. 4x forward), making it the more compelling value choice. Analysts rate Hyperfine, Inc. (HYPR) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, GE HealthCare Technologies Inc.

(GEHC) delivered a total return of +2. 9%, compared to -83. 1% for Hyperfine, Inc. (HYPR). Over 10 years, the gap is even starker: GEHC returned +2. 9% versus HYPR's -83. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), GE HealthCare Technologies Inc.

(GEHC) is the lower-risk stock at 1. 37β versus Hyperfine, Inc. 's 2. 63β — meaning HYPR is approximately 92% more volatile than GEHC relative to the S&P 500.

By revenue growth (latest reported year), Hyperfine, Inc.

(HYPR) is pulling ahead at 5. 2% versus 4. 8% for GE HealthCare Technologies Inc. (GEHC). On earnings-per-share growth, the picture is similar: Hyperfine, Inc. grew EPS 23. 2% year-over-year, compared to 4. 8% for GE HealthCare Technologies Inc.. Over a 3-year CAGR, HYPR leads at 25. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

GE HealthCare Technologies Inc.

(GEHC) is the more profitable company, earning 10. 1% net margin versus -262. 3% for Hyperfine, Inc. — meaning it keeps 10. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GEHC leads at 13. 4% versus -273. 4% for HYPR. At the gross margin level — before operating expenses — HYPR leads at 49. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for GEHC: 36.

9% to $84. 00.

In this comparison, GEHC (0.

2% yield) pays a dividend. HYPR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, GE HealthCare Technologies Inc.

(GEHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Hyperfine, Inc. (HYPR) carries a higher beta of 2. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GEHC: +2. 9%, HYPR: -83. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HYPR is a small-cap quality compounder stock; GEHC is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.